Ilaris (Novartis Pharmaceuticals Corporation)
Welcome to the PulseAid listing for the Ilaris drug offered from Novartis Pharmaceuticals Corporation. This pharmaceutical is classified as a HUMAN PRESCRIPTION DRUG. Below, you can view details for this drug, such as its dosage form, route of delivery, start market/end market dates, and more. We have also randomly listed additional pharmaceuticals used in the same HUMAN PRESCRIPTION DRUG drug type category.
LABELER NAME / MANUFACTURER: | Novartis Pharmaceuticals Corporation |
NON-PROPRIETARY NAME: | canakinumab |
SUBSTANCE NAME: | CANAKINUMAB |
TYPE: | HUMAN PRESCRIPTION DRUG |
PHARMA CLASS: | |
ROUTE: | SUBCUTANEOUS |
DOSAGE FORM: | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION |
MARKETING CATEGORY NAME: | BLA |
START MARKETING DATE: | 2009-06-18 |
END MARKETING DATE: | 0000-00-00 |
Ilaris HUMAN PRESCRIPTION DRUG Details:
Item Description | Ilaris from Novartis Pharmaceuticals Corporation |
LABELER NAME: | Novartis Pharmaceuticals Corporation |
DEA SCHEDULE: |
|
ACTIVE STRENGTH: | 150(mg/mL) |
START MARKETING DATE: | 2009-06-18 |
END MARKETING DATE: | 0000-00-00 |
PRODUCT ID: | 0078-0582_bb044a74-7007-446d-931b-0238d62db2fc |
PRODUCT NDC: | 0078-0582 |
APPLICATION NUMBER: | BLA125319 |
Other CANAKINUMAB Pharmaceutical Manufacturers / Labelers: